Abstract Number: VPB0943
Meeting: ISTH 2022 Congress
Theme: Venous Thromboembolism » Cancer Associated Thrombosis
Background: In patients with brain tumors, including gliomas (GM), venous thromboembolism (VTE) is a common complication (20–30%). A rise the platelet – derived circulating extracellular vesicles (EVs) level and activation system coagulation in plasma may contribute to VTE in patients GM.
Aims: To evaluate the use of routine laboratory tests (D-dimer, platelet count) in combination with thrombin generation test and relative abundance platelet-derived EVs in improving VTE risk factor stratification in patients with primary brain tumors.
Methods: In the present study, 11 patients with newly diagnosed GM and 10 healthy volunteers were analyzed. Platelet-derived EVs isolation and identification were performed using Exo-FACS kit (HansaBioMed Life Sciences, Estonia) and monoclonal antibodies CD41-PE/Cy7 as platelet specific markers, determination of the relative abundance by CytoFlex B4-R2-V2 (Beckman Coulter, USA). Thrombin generation test (TGT) were performed by the calibrated automated thrombography method (Thrombinoscope BV, Netherlands).
Results: In patients with GM, the relative abundance of the CD41+ EVs and D-dimer level were significantly higher than in controls (44.3 [40.5; 52.4]% vs 27.2 [22.9; 31]%, p = 0.002; 0.46 [0.38; 1.85] μg/ml FEU vs 0.36 [0.27; 0.40] μg/ml FEU, p = 0.03, respectively). There was a trend towards an increase in peak and rate thrombin formation (p = 0.06) in the GM group. Significant correlation between circulating CD41+ EVs and activation trombin (TGT parameter’s) in the GM group was shown (p < 0.05). During short follow-up period, 3 patients (27%) developed thrombosis, had tumour size more than 5 cm, thrombocytopenia < 150*10^9/L , increased VI (> 95 nmol/min) and D-dimer (> 5 μg/ml FEU).
Conclusion(s): The present pilot study showed that TGT and platelet EVs analysis, in combination with D-dimer and platelet count, can be used to assess the risk of VTE in GM patients. The results of the study need to be confirmed in a larger prospective study.
To cite this abstract in AMA style:
Melniсhnikova O, Zhilenkova J, Zolotova E, Sirotkina O, Pishchulov K, Vavilova T, Moiseeva O, Simakova M. Laboratory assessment of prothrombotic status in patients with primary brain tumors [abstract]. https://abstracts.isth.org/abstract/laboratory-assessment-of-prothrombotic-status-in-patients-with-primary-brain-tumors/. Accessed October 1, 2023.« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/laboratory-assessment-of-prothrombotic-status-in-patients-with-primary-brain-tumors/